MorphoSys AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOR research report →
About the company
MorphoSys AG is a commercial-stage biopharmaceutical company dedicated to the discovery, advancement, and marketing of innovative therapeutic antibodies aimed at treating cancer and autoimmune disorders. While its commercial operations are primarily situated in the United States, its development and partnership activities span globally. A key commercial offering is Tafasitamab, an antibody prescribed for various B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- CEO
- Arkadius Pichota
- IPO
- 2018
- Employees
- 464
- HQ
- Planegg, DE
Price Chart
- Market Cap
- $2.86B
- P/E
- -11.99
- P/S
- 10.48
- P/B
- 46.38
- EV/EBITDA
- -30.43
- Div Yield
- 0.00%
- Gross Margin
- 75.51%
- Op Margin
- -105.96%
- Net Margin
- -79.63%
- ROE
- -183.80%
- ROIC
- -14.13%
- Revenue
- $238.28M · -14.37%
- Net Income
- $-189,734,199 · -25.60%
- EPS
- $-1.38 · -25.11%
- Op Income
- $-252,475,802
- FCF YoY
- 21.79%
- 52W High
- $19.50
- 52W Low
- $4.18
- 50D MA
- $18.46
- 200D MA
- $14.73
- Beta
- 0.66
- Avg Volume
- 47.07K
Get TickerSpark's AI analysis on MOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MOR coverage
Recent articles, reports, and earnings notes.
No research on MOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MOR report →Similar companies
Peers in the same neighborhood.